Mesoblast (NASDAQ:MESO) Trading Down 2.2% – Should You Sell?

Mesoblast Limited (NASDAQ:MESO) fell 2.2% during mid-day trading on Wednesday . The company traded as low as $16.53 and last traded at $16.61. 24,805 shares changed hands during trading, a decline of 96% from the average session volume of 571,121 shares. The stock had previously closed at $16.98.

Analyst Upgrades and Downgrades

MESO has been the topic of a number of research analyst reports. Piper Sandler boosted their target price on shares of Mesoblast from $11.00 to $15.00 and gave the company an “overweight” rating in a research note on Thursday, December 19th. Maxim Group upgraded Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research note on Tuesday, September 24th. Finally, Jefferies Financial Group lowered Mesoblast from a “buy” rating to a “hold” rating in a report on Monday, December 23rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $13.50.

Mesoblast Price Performance

The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21. The business’s 50-day simple moving average is $13.59 and its two-hundred day simple moving average is $9.64.

Institutional Investors Weigh In On Mesoblast

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Signaturefd LLC grew its position in shares of Mesoblast by 128.7% in the third quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock valued at $45,000 after purchasing an additional 3,099 shares in the last quarter. GAMMA Investing LLC grew its holdings in Mesoblast by 22.1% during the 4th quarter. GAMMA Investing LLC now owns 6,711 shares of the company’s stock valued at $133,000 after buying an additional 1,213 shares in the last quarter. Perkins Coie Trust Co grew its holdings in Mesoblast by 15.0% during the 3rd quarter. Perkins Coie Trust Co now owns 11,500 shares of the company’s stock valued at $94,000 after buying an additional 1,500 shares in the last quarter. Rathbones Group PLC bought a new stake in shares of Mesoblast during the second quarter valued at about $95,000. Finally, XTX Topco Ltd purchased a new stake in shares of Mesoblast in the second quarter worth about $103,000. Institutional investors own 1.43% of the company’s stock.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.